本帖最后由 老马 于 2012-1-13 21:20 编辑 3 q9 d' v2 |" l: l
( i2 K" x/ J9 e! b4 m: O
爱必妥和阿瓦斯丁的比较
) i. p8 [' n% N* K1 ?
% [$ a' P! g5 W% G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ P h* q! R8 w5 h4 r9 i6 E+ V
9 B+ X ^5 c3 J2 ?/ C+ _
$ a, K2 t4 p! D0 i5 {% uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial// l: d* |" k$ d8 J, e, I9 F
==================================================8 x i6 @* S+ _8 C6 Y1 ]# h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 s) c- y$ S4 s8 I5 lPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 C! f3 ~$ D, K* vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' J' r7 i& B, X5 s
|